18.212.120.195
dgid:
enl:
npi:0
-Advertisement-
-Advertisement-
Conference Roundup
Retina

T&E regimen effective in the long-term neovascular AMD management

Posted on October 19, 2021

Results from a long-term study demonstrated that the treat-and-extend (T&E) regimen is effective in maintaining visual acuity in patients with neovascular age-related macular degeneration (nAMD) treated with regular intravitreal ranibizumab, aflibercept, bevacizumab, or brolucizumab for up to 7 years of treatment. For the Reno Study, US patients had received a minimum of 6 injections in the first year and a minimum of 3 injections in follow-up years 2 through 7, according to the results presented at the ASRS 2021 Annual Meeting.

The retrospective case series included 165 eyes from 137 treatment-naïve patients diagnosed with nAMD after August 2010 and who were treated with ranibizumab, aflibercept, bevacizumab, or brolucizumab for ≥1 year using a T&E regimen. Average baseline patient age was 78 years; 60% of patients were female. Mean follow-up was 5 years. The average best corrected visual acuity (BCVA) at baseline was 53 letters. Mean (SD) changes from baseline in BCVA were 8.2 (21.8) letters, 7.0 (25.0) letters, 4.4 (26.7) letters, 4.2 (27.6) letters, 4.4 (28.7) letters, 4.6 (26.2) letters, and 4.6 (37.0) letters for years 1, 2, 3, 4, 5, 6, and 7 respectively. The mean number of injections received by patients in year 1 was 8 and 6 in years 2 through 7. At the final follow-up, 23.4% of male eyes and 25.7% of female eyes had lost ≥15 ETDRS letters and 28.1% of male eyes and 27.7% of female eyes had gained ≥15 letters. The Treat-and-Extend regimen is an effective treatment option for patients, the researchers concluded.

Reference
Romero C. Efficacy of the treat-and-extend regimen in the management of neovascular age-related macular degeneration: 7-year results of the RENO Study. Presented at: 2021 Annual ASRS Meeting.

-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-
-Advertisement-